{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Familial+Atypical+Mole-Malignant+Melanoma+Syndrome&page=8", "query": { "condition": "Familial Atypical Mole-Malignant Melanoma Syndrome", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 380, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Familial+Atypical+Mole-Malignant+Melanoma+Syndrome&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Familial+Atypical+Mole-Malignant+Melanoma+Syndrome&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T16:22:32.043Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006385", "title": "Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-11-08", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 32, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006385" }, { "nct_id": "NCT01604889", "title": "A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2012-03-29", "completion_date": "2017-01-20", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 7, "location_summary": "Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01604889" }, { "nct_id": "NCT00436410", "title": "Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Adrenocortical Carcinoma", "Breast Cancer", "Colorectal Cancer", "Gastrointestinal Cancer", "Kidney Cancer", "Liver Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Sarcoma" ], "interventions": [ { "name": "colloidal gold-bound tumor necrosis factor", "type": "BIOLOGICAL" }, { "name": "electron microscopy", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2006-12", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2012-05-02", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436410" }, { "nct_id": "NCT05479812", "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "WTX-124", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Werewolf Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2022-08-15", "completion_date": "2026-04-22", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479812" }, { "nct_id": "NCT00004141", "title": "Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "Granulocyte-macrophage colony-stimulating factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 46, "start_date": "1998-08", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004141" }, { "nct_id": "NCT00089219", "title": "Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "IFA", "type": "BIOLOGICAL" }, { "name": "6MHP", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-11-20", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089219" }, { "nct_id": "NCT06409195", "title": "A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Melanoma Skin Cancers" ], "interventions": [ { "name": "SM-020 1% Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DermBiont, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-03-25", "completion_date": "2024-11", "has_results": false, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06409195" }, { "nct_id": "NCT07661966", "title": "Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma (Skin Cancer)", "NSCLC (Non-small Cell Lung Cancer)" ], "interventions": [ { "name": "Bright Light Therapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2026-10-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07661966" }, { "nct_id": "NCT05655312", "title": "MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Melanoma (Skin)", "Metastatic Melanoma", "Melanoma Stage IV", "Melanoma Stage III" ], "interventions": [ { "name": "[203Pb]VMT01", "type": "DRUG" }, { "name": "[212Pb]VMT01", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Perspective Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 300, "start_date": "2023-06-01", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 16, "location_summary": "Orange, California • Jacksonville, Florida • Miami, Florida + 12 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05655312" }, { "nct_id": "NCT00003556", "title": "Vaccine Therapy in Treating Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "ALVAC-hB7.1", "type": "BIOLOGICAL" }, { "name": "canarypox-hIL-12 melanoma vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1999-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-08", "last_synced_at": "2026-10-22T16:22:32.043Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003556" } ] }